A Phase 1 interventional study of HSG4112 and Placebo in Obesity, sponsored by Glaceum. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.
Sponsored by Glaceum · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Obesity with a site in Korea, Republic of — 35 open to participants now, 46 under way, 27 of them phase 3. Obesity · Korea, Republic of.
Among the 137 studies in Obesity with a site in Korea, Republic of, this one is the 99th largest by enrollment of the 117 interventional ones that give a count, is one of 12 that started in 2022, is one of 9 in phase 1, and was the 77th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →35 of the 137 studies in Obesity with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Korea, Republic of, United States, Brazil and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in Korea, Republic of, United States, Belgium and 7 more countries
Ages 6–11
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 13 more countries
Ages 18+
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 13 more countries
Ages 18+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–50
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 19 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 49 · Phase 4 7
First in 2005; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 120 across the 117 interventional studies, 704 across the 20 observational. Of the 76 that completed or were terminated, 10 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
65 of 137 have an industry lead sponsor. The 10 most frequent:
Glaceum is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Glaceum has 5 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
10 of the studies in Obesity with a site in Korea, Republic of that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 10 to your calendar (.ics) → With an account.
Among the 137 studies in Obesity with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Objective
i) To evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after single and multiple oral administration of high doses in healthy subjects.
ii) To evaluate the food effect on the pharmacokinetic characteristics of HSG4112 after a single oral administration of 1200 mg (6 tablets of HSG4112 200 mg) in healthy subjects.
Background
The previous phase 1 clinical trials investigating HSG4112 included dosage only up to 720 mg of HSG4112 in both healthy and obese subjects. Since obese patients have various comorbidities, unexpected drug interactions may occur due to concomitant drugs. Securing a 2- to 5-fold safety margin is needed to tolerate this issue. Therefore, this study is designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and food effects of high-dose HSG4112 in healthy subjects.
\<Part 1> This study is a randomized, open-label, single dosing, phase 1 clinical study. A unique randomization number will be assigned to each subject deemed eligible to participate in the study based on the inclusion/exclusion criteria. Each subject will be randomized to one of the two dose groups. 8 subjects will receive 800 mg of HSG4112 with a high-fat meal, and 12 subjects will be randomized to 2 different sequential groups. Each subject will receive a single dose of HSG4112 1200 mg via oral administration with a high-fat meal and in fasted condition, with a washout period of 21 days in between each dosing. When escalating the dose, the Investigator will review all of the available safety data from the preceding dose in a blinded manner to ensure if it is safe to escalate the dose. In order to evaluate safety and tolerability, assessments, such as vital signs, 12-lead ECG, laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed. Blood samples will be collected to evaluate the pharmacokinetic/pharmacodynamic characteristics of HSG4112.
\<Part 2> This study is a randomized, double-blind, placebo-controlled, multiple dosing, phase 1 clinical study. A unique randomization number will be assigned to each subject deemed eligible to participate in the study based on the inclusion/exclusion criteria. Each subject will be randomized to one of the two dose groups (800 mg or 1200 mg of HSG4112). In each dose group, 6 subjects will be randomized to receive 800 mg of HSG4112, and 2 subjects will be randomized to receive placebo, both with a high-fat meal. The subjects will be studied in a double-blind manner and will receive the investigational product (i.e., HSG4112 or placebo) via once-daily oral administration for 14 days. When escalating the dose, the Investigator will review all of the available safety data from the preceding dose in a blinded manner to ensure if it is safe to escalate the dose. In order to evaluate safety and tolerability, assessments, such as vital signs, 12-lead ECG, laboratory test, pregnancy test, physical examination, and adverse event monitoring will be performed. Blood samples will be collected to evaluate the pharmacokinetic/pharmacodynamic characteristics of HSG4112.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) between 18 and 24.9.
Exclusion Criteria:
One or more of the following laboratory test results at screening:
Unable or unwilling to use acceptable methods for themselves or their spouse/partner during the entire study period and up to 28 days after the last dosing and subjects who satisfy at least one of the pregnancy-related criteria below:
females of childbearing potential confirmed "positive" in a pregnancy test
"females of childbearing potential" refer to females who have experienced menarche and have not undergone a successful surgical sterilization procedure (i.e., hysterectomy, bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy) or is not menopause (i.e., 12 months without menstruation).
Acceptable contraceptive methods include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dosing of HSG4112 800 mg
Drug: HSG4112
Single oral dosing of HSG4112 1200 mg with a high-fat meal or fasting condition, with a washout period of 21 days in between each dosing
Drug: HSG4112
Multiple oral dosing of HSG4112 1200 mg for 14 days
Drug: HSG4112
Multiple oral dosing of placebo 800 mg for 14 days
Drug: Placebo
Multiple oral dosing of HSG4112 1200 mg for 14 days
Drug: HSG4112
Multiple oral dosing of placebo 1200 mg for 14 days
Drug: Placebo
Once-daily oral adminstration
Also known as: 2-(8,8 dimethyl 2,3,4,8,9,10 hexahydropyrano[2,3 f]chromen 3 yl) 5 ethoxyphenol
Once-daily oral adminstration
Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112
Maximum Plasma Concentration of HSG4112 (Cmax)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Maximum Plasma Concentration of HSG4112 at Steady State
Maximum Plasma Concentration of HSG4112 at Steady State (Cmax,ss)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Minimum Plasma Concentration of HSG4112 at Steady State
Minimum Plasma Concentration of HSG4112 at Steady State (Cmin,ss)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Average Plasma Concentration of HSG4112 at Steady State
Average Plasma Concentration of HSG4112 at Steady State (Cavg,ss)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity
Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity (AUCinf)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity at Steady State
Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to Infinity at Steady State (AUCinf,ss)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval
Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval (AUCtau)
Time frame: Hour 0 to 24
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval at Steady State
Area Under the Plasma Concentration-Time Curve of HSG4112 Over Dosing Interval at Steady State (AUCtau,ss)
Time frame: Hour 0 to 24
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point
Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point (AUClast)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point at Steady State
Area Under the Plasma Concentration-Time Curve of HSG4112 from Time Zero to the Last Measurable Point at Steady State (AUClast,ss)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Half-Life of HSG4112
Half-life of HSG4112 (T1/2)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Half-Life of HSG4112 at Steady State
Half-life of HSG4112 at Steady State (T1/2,ss)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112
Time to Maximum Observed Plasma of HSG4112 (Tmax)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Time to Maximum Observed Plasma Concentration of HSG4112 at Steady State
Time to Maximum Observed Plasma Concentration of HSG4112 at Steady State (Tmax,ss)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Oral Clearance of HSG4112
Oral Clearance of HSG4112 (CL/F)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Oral Clearance of HSG4112 at Steady State
Oral Clearance of HSG4112 at Steady State (CLss/F)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Volume of Distribution of HSG4112
Volume of Distribution of HSG4112 (Vd/F)
Time frame: Hour 0 to 192
Pharmacokinetic Assessment by Volume of Distribution of HSG4112 at Steady State
Volume of Distribution of HSG4112 at Steady State (Vdss/F)
Time frame: Hour 0 to 192
Safety and Tolerability Assessment by Adverse Event Monitoring
Number of participants with observed advese events
Time frame: Day 1 to 9 following the last administration
Safety and Tolerability Assessment by Number of Participants with Change in Vital Signs
Number of participants with clinically significant change in vital signs including blood pressure (mmHg) measured with blood pressure monitor, heart rate (beats per minute) measured with pulse oximeter, and body temperature (degrees Celcius) measured with thermometer
Time frame: Day 1 to 9 following the last administration
Safety and Tolerability Assessment by Number of Patients with Change in Physical Examination
Number of participants with clinically significant change in physical examination
Time frame: Day 1 to 9 following the last administration
Safety and Tolerability Assessment by Number of Participants with Change in Laboratory Test
Number of participants with clinically significant change in laboratory test assessed through hematology, blood biochemistry, urinalysis, and blood coagulation test
Time frame: Day 1 to 9 following the last administration
Safety and Tolerability Assessment by Number of Participants with Change in 12-Lead Electrocardiogram
Number of participants with clinically significant change in 12-lead electrocardiogram
Time frame: Day 1 to 9 following the last administration
Pharmacodynamic Assessment by Change in Body Weight [Part 2]
Change in body weight
Time frame: Days 1 to 17, Day 18, Day 20, Day 22 post-dose before first meal
Pharmacodynamic Assessment by Change in Waist Circumference [Part 2]
Change in waist circumference
Time frame: Day 1, Day 8, Day 15, Day 22 post-dose before first meal
Pharmacodynamic Assessment by Change in Body Fat Mass [Part 2]
Change in body fat mass
Time frame: Day 1, Day 8, Day 15, Day 22 post-dose before first meal
Pharmacodynamic Assessment by Change in Body Fat Percentage [Part 2]
Change in body fat percentage
Time frame: Day 1, Day 8, Day 15, Day 22 post-dose before first meal
Pharmacodynamic Assessment by Change of Biomarkers [Part 2]
Measurement of biomarkers including leptin, adiponectin, insulin, C-peptide (connecting peptide), IL6 (interleukin 6), TNF-alpha (tumor necrosis factor alpha), and CCL2 (C-C motif ligand 2) from baseline to day of last dosing will be combined to assess the weight loss effect of HSG4112
Time frame: Day 1 and 14 pre-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Dec 2022, 7 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HSG4112
Glaceum